©NIJRMS
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 6 Issue 2 Page 6-10 2025

https://doi.org/10.59298/NIJRMS/2025/6.2.610

The Impact of Immunosuppressive Therapies on Childhood Immunity and Infection Risk

Nakaziya Obutuzi G.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Immunosuppressive therapies are critical in managing pediatric autoimmune diseases, organ transplantation, and malignancies. However, these treatments profoundly impact immune function, increasing infection susceptibility and altering vaccine efficacy. This article explores the mechanisms of immunosuppressive agents, including corticosteroids, calcineurin inhibitors, anti-proliferative agents, and biologics, and their effects on childhood immunity. The heightened infection risk, impaired vaccine responses, and potential delays in immune development highlight the need for targeted prevention strategies. Infection prophylaxis, optimized vaccination schedules, and regular immune monitoring are essential to mitigate risks. Future research should focus on balancing disease control with immune preservation to enhance long-term health outcomes in immunocompromised children.

Keywords: Immunosuppressive therapy, pediatric immunity, infection risk, vaccination, immune modulation

INTRODUCTION

Immunosuppressive therapies play a critical role in managing various pediatric conditions, including autoimmune diseases, organ transplantation, and malignancies [1]. These treatments help control aberrant immune responses, prevent graft rejection, and improve survival outcomes in children with serious illnesses [2]. However, the suppression of immune function comes with significant challenges, particularly an increased susceptibility to infections and potential alterations in vaccine responses [3]. Children receiving immunosuppressive therapy often experience impaired immune surveillance, which can lead to a higher risk of opportunistic infections and more severe disease courses [4]. This vulnerability necessitates careful monitoring and the implementation of preventive strategies such as antimicrobial prophylaxis, immunoglobulin replacement, and tailored vaccination protocols [5]. However, vaccine-induced immunity in immunosuppressed children is often suboptimal, as their immune systems may not generate robust or long-lasting protective responses [6]. The degree of immunosuppression, type of therapy, and timing of vaccination all influence vaccine efficacy, highlighting the need for individualized immunization plans [7]. Recent advances in immunology have improved our understanding of how different immunosuppressive agents impact various components of the immune system [8]. Corticosteroids, calcineurin inhibitors, cytotoxic drugs, and biologic agents all exert distinct effects on immune cells, influencing infection risk and vaccine response in different ways [9]. Recognizing these nuances is crucial for optimizing pediatric care, balancing immunosuppression with adequate protection against infections [10]. Given these complexities, a multidisciplinary approach involving pediatricians, immunologists, and infectious disease specialists is essential for developing evidence-based strategies to minimize risks while maintaining treatment efficacy [11]. This review aims to explore the effects of immunosuppressive therapies on infection susceptibility and vaccine responses in pediatric patients, with a focus on current challenges, emerging strategies, and recommendations for improving clinical outcomes.

Mechanisms of Immunosuppression

Immunosuppressive agents function by dampening immune activity, reducing inflammation, and preventing immune-mediated damage [12]. These therapies are essential for managing autoimmune diseases, preventing transplant rejection, and treating malignancies [13]. Their mechanisms vary, targeting different components of the immune system to modulate immune responses effectively [14].

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

1. Corticosteroids: These agents exert broad immunosuppressive effects by inhibiting the activation and proliferation of immune cells [15]. They suppress pro-inflammatory cytokine production, impair antigen presentation, and reduce leukocyte migration [16]. While effective, long-term corticosteroid use increases the risk of infections and metabolic complications [15].

2. Calcineurin Inhibitors (Tacrolimus, Cyclosporine): These drugs selectively inhibit T-cell activation by blocking calcineurin, a critical signaling molecule required for cytokine production [17]. By preventing interleukin-2 (IL-2) synthesis, they impair T-cell proliferation, making them essential in preventing organ transplant rejection. However, their use is associated with nephrotoxicity and increased susceptibility to opportunistic infections [17,18].

3. Anti-Proliferative Agents (Azathioprine, Mycophenolate Mofetil): These medications inhibit DNA synthesis, thereby blocking lymphocyte proliferation [19]. By impairing adaptive immune responses, they help control autoimmune diseases and prevent transplant rejection [20]. However, they also increase the risk of myelosuppression and secondary infections [21].

4. Biologic Therapies (TNF Inhibitors, IL-6 Blockers, B-cell Depleting Agents): These targeted therapies modulate specific immune pathways. Tumor necrosis factor (TNF) inhibitors and interleukin-6 (IL-6) blockers reduce inflammation by disrupting cytokine signaling, while B-cell depleting agents (e.g., rituximab) impair humoral immunity [22,23]. These therapies improve disease control but can lead to reactivation of latent infections, such as tuberculosis.

Understanding the distinct mechanisms of immunosuppressive agents is crucial for optimizing treatment regimens while minimizing adverse effects [24]. A tailored approach based on disease pathology and patient-specific risk factors is necessary to balance efficacy and safety [25].

Effects on Childhood Immunity

Immunosuppressive therapies significantly alter immune function in children, increasing infection risk, impairing vaccine responses, and potentially affecting long-term immune development.

1. Increased Infection Risk

Immunosuppressive agents weaken both innate and adaptive immune defenses, making children more susceptible to bacterial, viral, fungal, and opportunistic infections. Common infections include respiratory tract infections, urinary tract infections, and bloodstream infections [26]. Reactivation of latent viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), is frequently observed, especially in transplant recipients and those on prolonged immunosuppressive regimens [27]. Opportunistic pathogens, including Pneumocystis jirovecii and invasive fungal species, pose significant risks, necessitating prophylactic antimicrobial strategies [28].

2. Altered Vaccine Responses

Immunosuppressive treatments can impair vaccine-induced immunity by reducing seroconversion rates, antibody titers, and long-term protection [29]. Live attenuated vaccines (e.g., measles-mumps-rubella [MMR], varicella) are contraindicated due to the risk of uncontrolled vaccine strain replication [30]. Inactivated and subunit vaccines may elicit weaker responses, requiring booster doses or modified immunization schedules [31]. Timing of vaccination is crucial, as administering vaccines during periods of minimal immunosuppression can improve immune responses [32].

3. Delayed Immune Development

Prolonged immunosuppression in early childhood can disrupt normal immune maturation, potentially leading to long-term immune deficits. Reduced thymic output of naïve T cells and impaired development of memory T-cell responses may result in diminished immune resilience against future infections [33]. Some immunosuppressive agents can alter B-cell function, affecting humoral immunity and long-term antibody production [34]. Understanding these effects is critical for optimizing infection prevention strategies and vaccination protocols in immunosuppressed pediatric patients [35]. Individualized approaches can help mitigate risks while ensuring adequate disease protection.

Strategies for Risk Mitigation

Managing the risks associated with immunosuppressive therapies in pediatric patients requires a comprehensive approach that includes infection prevention, optimized vaccination strategies, and regular monitoring [36].

1. Infection Prevention

Prophylactic Antimicrobials: Children receiving immunosuppressive therapy, particularly those at high risk for opportunistic infections, may benefit from prophylactic antibiotics, antifungals, and antivirals. For example, trimethoprim-sulfamethoxazole is commonly used to prevent Pneumocystis jirovecii pneumonia, while antifungal prophylaxis may be indicated in patients undergoing prolonged immunosuppression [37]. Immunoglobulin Replacement: In cases of severe B-cell depletion or hypogammaglobulinemia, intravenous or subcutaneous immunoglobulin therapy can provide passive immunity against infections [38].

Stringent Hygiene Practices: Hand hygiene, avoiding sick contacts, and minimizing exposure to potential pathogens are essential preventive measures [39]. Educating families and caregivers on infection control strategies is crucial for reducing infection risk.

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

2.Optimized Vaccination Strategies

Pre-Immunization Assessment: Baseline serological testing can help determine existing immunity and guide vaccination strategies before the initiation of immunosuppressive therapy [40].

Early Vaccination: Whenever possible, vaccines should be administered before the start of immunosuppressive treatment to maximize immune response [41]. Live vaccines should be given at least four weeks before therapy initiation [41].

Post-Treatment Booster Doses: After immunosuppressive therapy, reassessment of vaccine immunity is necessary, and booster doses may be required to restore adequate protection [42]. Inactivated vaccines can often be administered during therapy, but response rates may be reduced [42].

3. Monitoring and Early Detection

Regular Screening for Infections: Routine surveillance for bacterial, viral, and fungal infections allows for early diagnosis and timely treatment [43]. This includes periodic testing for latent infections, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV), particularly in transplant recipients [43,44].

Immune Function Monitoring: Assessing lymphocyte counts, immunoglobulin levels, and vaccine titers can help tailor immunosuppressive therapy and determine the need for additional interventions [45].

CONCLUSION

Immunosuppressive therapies are indispensable in pediatric medicine, providing essential disease control in conditions such as autoimmune disorders, organ transplantation, and malignancies. However, their impact on immune function increases the risk of infections and alters vaccine responses. A well-balanced approach that integrates infection prevention strategies, tailored vaccination protocols, and vigilant monitoring is essential for mitigating these risks. As research advances, immune-modulating therapies and novel vaccination strategies will further enhance the safety and effectiveness of immunosuppressive treatments, improving long-term outcomes for immunocompromised children.

REFERENCES

1. Hussain Y, Khan H. Immunosuppressive drugs. In: Elsevier eBooks. 2021. p. 726–40. doi:10.1016/b978-0-12-818731-9.00068-9
2. Zakrzewski JL, Van Den Brink MRM, Hubbell JA. Overcoming immunological barriers in regenerative medicine. Nature Biotechnology. 2014;32(8):786–94. doi:10.1038/nbt.2960
3. Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clinical Microbiology Reviews. 2019;32(2):. doi:10.1128/cmr.00084-18
4. Kurizky PS, Neto LLDS, Aires RB, Da Mota LMH, Gomes CM. Opportunistic tropical infections in immunosuppressed patients. Best Practice & Research Clinical Rheumatology. 2020;34(4):101509. doi:10.1016/j.berh.2020.101509
5. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of Antibiotics and antibiotic resistance, and their Impacts on Drug Development: A Narrative review. Pharmaceuticals. 2023;16(11):1615. doi:10.3390/ph16111615
6. Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children—an overview for physicians. European Journal of Pediatrics. 2021;180(7):2035–47. doi:10.1007/s00431-021-03997-1
7. Alnaimat F, Sweis JJG, Jansz J, Modi Z, Prasad S, AbuHelal A, et al. Vaccination in the era of immunosuppression. Vaccines. 2023;11(9):1446. doi:10.3390/vaccines11091446
8. Xu Z, Chu M. Advances in immunosuppressive agents based on signal pathway. Frontiers in Pharmacology. 2022;13. doi:10.3389/fphar.2022.917162
9. Hussain Y, Khan H. Immunosuppressive drugs. In: Elsevier eBooks. 2021. p. 726–40. doi:10.1016/b978-0-12-818731-9.00068-9
10. Tennant R, Graham J, Kern J, Mercer K, Ansermino JM, Burns CM. A scoping review on pediatric sepsis prediction technologies in healthcare. Npj Digital Medicine. 2024;7(1). doi:10.1038/s41746-024-01361-9
11. Noij L, Terheggen-Lagro S, Muselaers E, Whittaker E, Gosling J, Brackel C, et al. A multidisciplinary approach: management and rehabilitation of children with pediatric post-COVID-19 condition. The Pediatric Infectious Disease Journal. 2024;43(9):880–4. doi:10.1097/inf.0000000000004408
12. Hussain Y, Khan H. Immunosuppressive drugs. In: Elsevier eBooks. 2021. p. 726–40. doi:10.1016/b978-0-12-818731-9.00068-9
13. Fu Y, Feng C, Qin S, Xing Z, Liu C, Liu Z, et al. Breaking barriers: advancing cellular therapies in autoimmune disease management. Frontiers in Immunology. 2024;15. doi:10.3389/fimmu.2024.1503099

14. Kaminogawa S, Nanno M. Modulation of immune functions by foods. Evidence-based Complementary and Alternative Medicine. 2004;1(3):241–50. doi:10.1093/ecam/neh042
15. Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531462/
16. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nature Reviews Immunology. 2017;17(4):233–47. doi:10.1038/nri.2017.1
17. Safarini OA, Keshavamurthy C, Patel P. Calcineurin inhibitors. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK558995/
18. Kaye AD, Shah SS, Johnson CD, De Witt AS, Thomassen AS, Daniel CP, et al. Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant patients. Current Issues in Molecular Biology. 2024;47(1):2. doi:10.3390/cimb47010002
19. Claeys E, Vermeire K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects. Journal of Immunological Sciences. 2019;3(4):14–21. doi:10.29245/2578-3009/2019/4.1178
20. Meneghini M, Bestard O, Grinyo JM. Immunosuppressive drugs modes of action. Best Practice & Research Clinical Gastroenterology. 2021;54–55:101757. doi:10.1016/j.bpg.2021.101757
21. Jewett A, Tseng HC. Immunotherapy. In: Elsevier eBooks. 2017. p. 504–29. doi:10.1016/b978-0-323-39307-2.00035-7
22. Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases. The Journal of Experimental Medicine. 2024;221(11). doi:10.1084/jem.20240806
23. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy? Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1126421
24. Job KM, Roberts JK, Enioutina EY, Illamola SM, Kumar SS, Rashid J, et al. Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Expert Opinion on Drug Metabolism & Toxicology. 2021;17(7):747–65. doi:10.1080/17425255.2021.1943356
25. Dekkers T, Hertroijs DFL. Tailored Healthcare: Two perspectives on the development and use of patient profiles. Advances in Therapy. 2018;35(9):1453–9. doi:10.1007/s12325-018-0765-2
26. De Moraes-Pinto MI, Ferrarini MAG. Opportunistic infections in pediatrics: when to suspect and how to approach. Jornal De Pediatria. 2019;96:47–57. doi:10.1016/j.jped.2019.09.008
27. Speth P, Jargosch M, Seiringer P, Schwamborn K, Bauer T, Scheerer C, et al. Immunocompromised Patients with Therapy-Refractory Chronic Skin Diseases Show Reactivation of Latent Epstein–Barr Virus and Cytomegalovirus Infection. Journal of Investigative Dermatology. 2021;142(3):549-558.e6. doi:10.1016/j.jid.2021.07.171
28. Truong J, Ashurst JV. Pneumocystis jirovecii Pneumonia. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482370/
29. Van Aalst M, Langedijk AC, Spijker R, De Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. Vaccine. 2018;36(39):5832–45. doi:10.1016/j.vaccine.2018.07.039
30. Desjardins M, Mitre X, Sherman AC, Walsh SR, Cheng MP, Kanjilal S, et al. Safety of Live-Attenuated measles, mumps, and rubella vaccine administered within 2 years of hematopoietic cell transplant. Open Forum Infectious Diseases. 2021;8(12). doi:10.1093/ofid/ofab504
31. Mahor H, Mukherjee A, Sarkar A, Saha B. Anti-leishmanial therapy: Caught between drugs and immune targets. Experimental Parasitology. 2022;245:108441. doi:10.1016/j.exppara.2022.108441
32. Alnaimat F, Sweis JJG, Jansz J, Modi Z, Prasad S, AbuHelal A, et al. Vaccination in the era of immunosuppression. Vaccines. 2023;11(9):1446. doi:10.3390/vaccines11091446
33. Bloemers BLP, Bont L, De Weger RA, Otto SA, Borghans JA, Tesselaar K. Decreased Thymic Output Accounts for Decreased Naive T Cell Numbers in Children with Down Syndrome. The Journal of Immunology. 2011;186(7):4500–7. doi:10.4049/jimmunol.1001700
34. Thaunat O, Koenig A, Leibler C, Grimbert P. Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. Journal of the American Society of Nephrology. 2016;27(7):1890–900. doi:10.1681/asn.2015070781

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

35. Marinho AKBB. Vaccination in children with immune-mediated disorders. Jornal De Pediatria. 2022;99:S62–9. doi:10.1016/j.jped.2022.11.008
36. Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children—an overview for physicians. European Journal of Pediatrics. 2021;180(7):2035–47. doi:10.1007/s00431-021-03997-1
37. Ibrahim A, Chattaraj A, Iqbal Q, Anjum A, Rehman MEU, Aijaz Z, et al. Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients. Avicenna Journal of Medicine. 2023;13(01):023–34. doi:10.1055/s-0043-1764375
38. Arumugham VB, Rayi A. Intravenous immunoglobulin (IVIG). StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554446/
39. Toney-Butler TJ, Gasner A, Carver N. Hand hygiene. StatPearls - NCBI Bookshelf. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470254/
40. Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving Vaccine-Induced Immunity: Can Baseline predict Outcome? Trends in Immunology. 2020;41(6):457–65. doi:10.1016/j.it.2020.04.001
41. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary. Journal of the Canadian Association of Gastroenterology. 2018;2(4):149–52. doi:10.1093/jcag/gwy069
42. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies. Journal of Cutaneous Medicine and Surgery. 2018;23(1):50–74. doi:10.1177/1203475418811335
43. Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C, et al. Diagnosis of invasive fungal infections: challenges and recent developments. Journal of Biomedical Science. 2023;30(1). doi:10.1186/s12929-023-00926-2
44. Fishman JA. Overview: Cytomegalovirus and the herpesviruses in transplantation. American Journal of Transplantation. 2013;13:1–8. doi:10.1111/ajt.12002
45. Foettinger F, Pilz G, Wipfler P, Harrer A, Kern JM, Trinka E, et al. Immunomodulatory aspects of therapeutic plasma exchange in Neurological Disorders—A pilot study. International Journal of Molecular Sciences. 2023;24(7):6552. doi:10.3390/ijms24076552

CITE AS: Nakaziya Obutuzi G. (2025). The Impact of Immunosuppressive Therapies on Childhood Immunity and Infection Risk. Newport International Journal of Research in Medical Sciences, 6(2):6-10 https://doi.org/10.59298/NIJRMS/2025/6.2.610